Targeting CD38/ ADP-ribosyl cyclase as a novel therapeutic strategy for identification of three potent agonists for leukopenia treatment.

MLA

Liu, Yuanzhi, et al. “Targeting CD38/ ADP-Ribosyl Cyclase as a Novel Therapeutic Strategy for Identification of Three Potent Agonists for Leukopenia Treatment.” Pharmacological Research, vol. 200, Feb. 2024, p. 107068. EBSCOhost, https://doi.org/10.1016/j.phrs.2024.107068.

APA

Liu, Y., Zhang, L., Wang, L., Tang, X., Wan, S., Huang, Q., Ran, M., Shen, H., Yang, Y., Chiampanichayakul, S., Tima, S., Anuchapreeda, S., & Wu, J. (2024). Targeting CD38/ ADP-ribosyl cyclase as a novel therapeutic strategy for identification of three potent agonists for leukopenia treatment. Pharmacological Research, 200, 107068. https://doi.org/10.1016/j.phrs.2024.107068

Chicago

Liu, Yuanzhi, Linwei Zhang, Long Wang, Xiaoqin Tang, Shengli Wan, Qianqian Huang, Mei Ran, et al. 2024. “Targeting CD38/ ADP-Ribosyl Cyclase as a Novel Therapeutic Strategy for Identification of Three Potent Agonists for Leukopenia Treatment.” Pharmacological Research 200 (February): 107068. doi:10.1016/j.phrs.2024.107068.